menu
    • menu

    Company profile for Immusoft Corporation

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immusoft is developing a cutting edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP™). ISP entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per sec...
    Immusoft is developing a cutting edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP™). ISP entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immusoft CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    454 N 34th St. Seattle, WA 98103
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immusoft.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immusoft Awarded $15 M in Funding from the California Institute
    Immusoft Awarded $15 M in Funding from the California Institute

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264486/0/en/Immusoft-Awarded-15-Million-in-Funding-from-the-California-Institute-for-Regenerative-Medicine.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Immusoft Gets FDA Rare Pediatric Disease Designation For ISP-002
    Immusoft Gets FDA Rare Pediatric Disease Designation For ISP-002

    26 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immusoft-receives-fda-rare-pediatric-disease-designation-for-isp-002-to-treat-mucopolysaccharidosis-type-ii-302669767.html

    PR NEWSWIRE
    26 Jan 2026
    Share Share
    Immusoft Secures FDA Orphan Status for ISP-002 in MPS II
    Immusoft Secures FDA Orphan Status for ISP-002 in MPS II

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immusoft-secures-fda-orphan-drug-designation-for-isp-002-in-mps-ii-a-progressive-lysosomal-storage-disease-302642225.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Immusoft Receives FDA Fast Track Designation for ISP-001
    Immusoft Receives FDA Fast Track Designation for ISP-001

    21 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immusoft-receives-fda-fast-track-designation-for-isp-001-a-first-in-class-engineered-b-cell-therapy-for-mps-i-302589744.html

    PR NEWSWIRE
    21 Oct 2025
    Share Share
    Immusoft to Present Positive Results at ASGCT 2025
    Immusoft to Present Positive Results at ASGCT 2025

    13 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immusoft-to-present-data-at-asgct-2025-demonstrating-positive-results-from-the-worlds-first-engineered-b-cell-in-a-human-clinical-trial-302453309.html

    PR NEWSWIRE
    13 May 2025
    Share Share
    Immusoft To Announce Phase 1 Engineered B Cell Therapy Data
    Immusoft To Announce Phase 1 Engineered B Cell Therapy Data

    23 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immusoft-to-announce-positive-phase-1-data-for-first-engineered-b-cell-therapy-in-a-clinical-trial-302255551.html

    PR NEWSWIRE
    23 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search